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Abstract: Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short
survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may
be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM
using semi-supervised source extraction and single-slice Magnetic Resonance Spectroscopic Imaging
(MRSI). Nevertheless, GBMs are heterogeneous and single-slice studies could prevent obtaining relevant
information. The purpose of this work was to evaluate whether a multi-slice MRSI approach, acquiring
consecutive grids across the tumor, is feasible for preclinical models and may produce additional insight
into therapy response. Nosological images were analyzed pixel-by-pixel and a relative responding
volume, the Tumor Responding Index (TRI), was defined to quantify response. Heterogeneous response
levels were observed and treated animals were ascribed to three arbitrary predefined groups: high
response (HR, n = 2), TRI = 68.2 ± 2.8%, intermediate response (IR, n = 6), TRI = 41.1 ± 4.2% and low
response (LR, n = 2), TRI = 13.4 ± 14.3%, producing therapy response categorization which had not
been fully registered in single-slice studies. Results agreed with the multi-slice approach being feasible
and producing an inverse correlation between TRI and Ki67 immunostaining. Additionally, ca. 7-day
oscillations of TRI were observed, suggesting that host immune system activation in response to treatment
could contribute to the responding patterns detected.
Keywords: glioma; GL261; orthotopic tumors; therapy response; TMZ; immune response;
nosological images
1. Introduction
Glioblastoma (GBM) is the most common and aggressive glial primary tumor with a survival
average of 14–15 months, even after application of standard treatment [1]. Temozolomide (TMZ)
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plus radiotherapy is the regular therapeutic choice for such treatment [2] and produces the best
survival rates.
Magnetic resonance techniques are the most suitable approaches to perform diagnosis and
therapy response follow-up in brain tumors as GBM. These techniques could provide anatomical
information (MRI, magnetic resonance imaging) or information of the metabolomic profile (MRS,
magnetic resonance spectroscopy). Still, magnetic resonance spectroscopic imaging could provide
both, metabolomic information superimposed to anatomical information. Namely, the difference
between MRS and MRSI is that MRS consists in acquiring single spectrum from a certain volume,
whereas in MRSI multiple signals from a grid of voxels are acquired, allowing to gather metabolomic
information from different regions of the studied tissue [3].
Radiological and clinical guidelines are used to evaluate GBM response to therapy, particularly
through the application of the response assessment in neuro-oncology (RANO) criteria [4] and Response
Evaluation Criteria in Solid Tumors (RECIST) criteria [5]. Nevertheless, magnetic resonance imaging
(MRI) information is not always precise enough for this due to pseudoresponse and pseudoprogression
appearance in some cases [6]. In this sense, magnetic resonance spectroscopy (MRS) and magnetic
resonance spectroscopic imaging (MRSI) might be a useful supplementary tool for this purpose [7],
as MRS/MRSI are also used for monitoring the molecular properties and metabolic heterogeneity of brain
tumors [8,9]. Furthermore, the rich information contained in MRS/MRSI signals makes them ideally
suited to the application of statistical pattern recognition (PR) techniques [10], which are used nowadays to
perform automatic categorization of individual MRSI data obtained from different types of tissue. This
approach can be applied to MRSI data from human brain tumors [11] and preclinical animal models [12].
PR techniques have also been proven useful to detect and characterize tumor response to therapy [13] with
generation of nosological images of therapy response. Briefly, nosological images are those in which each
pixel is colored according to a class (e.g., tumor and normal tissue). For MRSI, each pixel corresponds to an
individual spectrum, and, in our study, pixel classification is performed by mathematical PR.
Additionally, Ki67 staining for proliferation rate has been reported as a good response biomarker
for preclinical [14] and clinical GBM, also related to patient survival and time to recurrence [15].
However, Ki67 studies require invasive procedures (biopsy sampling), and thus the development of
non-invasive techniques that would correlate with this biomarker would be highly desirable.
The preclinical glioblastoma model of GL261 cells growing into C57BL/6 mice has been used for
more than 20 years in different therapy evaluation approaches [16–18]. In addition, work from our
group on TMZ-treated C57BL/6 mice harboring orthotopic GL261 GBM has demonstrated an increase
in survival rate (33.9 ± 11.7 days, n = 38), compared to control GL261 GBM mice with no treatment
(21.50 ± 3.7 days, n = 61), from [13,18] and additional unpublished data from our group.
In previous studies from our group, we could demonstrate that there was a significant correlation
when comparing the MRSI-based nosological maps with the proliferation rate (Ki67) of the tumors
(higher proliferation rate meaning lack of response or relapse in case of treated tumors) [13]. However,
only the central part of the tumor was analyzed (single MRSI slice). Thus, we thought that it would be
of interest to evaluate the tumors using a multi-slice approach, as it has been demonstrated that GBMs
display intratumoral heterogeneity [19,20] that may influence tumor aggressiveness or response to
chemotherapies such as TMZ [21]. Accordingly, in this work, we have set-up a multi-slice protocol for
MRSI evaluation, and performed as well the correlation of nosological images with the proliferation
rate of the tumors through Ki67 immunostaining. Our goal was to determine if substantial differences
could be proven to exist in the different zones of the tumor undergoing classical TMZ administration
protocol and sampled by nosological imaging, as observed in previous studies from our group [13,18].
2. Results
Two groups of treated mice were used in this work (please refer to Materials and Methods Sections 4.2
and 4.3 for further detail on groups). All spectra from MRSI matrices were aligned before performing PR
analysis (see Section 4.4.2 of Materials and Methods for additional details on preprocessing).
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2.1. Group A: Cases Starting Therapy at Day 11 p.i.: Inclusion into Different Groups of Response Level
Twelve animals were chosen for longitudinal multi-slice MRSI studies (see Materials and Methods
Section): six mice (C971, C974, C975, C1022, C1023 and C1026) were classified as intermediate response
(IR) cases and two mice (C979 and C981) were classified as low response (LR) cases. All but one case
(C974) were euthanized at the time point for which criteria for inclusion into IR or LR groups were
accomplished. Regarding case C974 (IR), it was maintained alive until the endpoint to follow-up the
possible TRI changes along time. No high response (HR) cases were found in this first part of the
experiment (the maximum calculated TRI was of 46.5%, see also Section 2.2). In addition, four control
cases (C1109, C1110, C1111 and C1112) were also analyzed with multi-slice MRSI studies, although
only one measurement was carried out at Days 11 p.i., 13 p.i., 16 p.i. and 13 p.i., respectively, and they
were euthanized when tumor volumes were about 70.2 ± 18.7 mm3.
It is worth mentioning that in addition to the four control cases explored in this work, 28 additional
cases from previous work from our group were added to confirm consistent evolution of the pattern
by MRI follow-up, reaching a total of n = 32 control cases (Figure S1).
Table S1 shows relevant parameters for these cases: tumor volume pre-treatment, tumor volume
at euthanasia, RECIST criteria classification of response to therapy and TRI criteria classification of
response to therapy).
In addition, significant differences (p < 0.05) were observed between body weight evolution
between all treated groups (Figure S2).
2.1.1. TRI and Nosological Images Evolution vs. Tumor Volume Evolution
IR cases: the relationship between TRI and tumor volume evolution of IR cases is shown in
Figures 1 and 2. Euthanasia was performed when TRI values met the inclusion criteria for IR class,
namely: TRI ranging between 35–65% and tumor volume meeting criteria for “stable disease” according
to RECIST (see Material and Methods, Section 4.5 for TRI calculation). These criteria were met in
five out of six IR cases at the euthanization time. The mean TRI value of these five cases (C971, C975,
C1022, C1023 and C1026) was 44.1 ± 4.2%. The remaining case (C974) met IR conditions during part
of the evolution period, and was not euthanized but followed-up until endpoint, and will be described
in a separate section. In IR cases, TRI values increased after the second therapy cycle, coinciding
with tumor growth arrest (stable disease stage by RECIST criteria). The maximum variation in tumor
volume in the stable disease period of IR cases was of 17.6%. Figure 1 shows two chosen examples of
IR cases: C971 and C1022 (Figure 1A,B, respectively). In case C1022, TRI increase (46.5%) was found
four days after the second therapy cycle, during tumor growth arrest. On the other hand, in case C971
(Figure 1A), we can observe that TRI also increased its value during the “stable disease” stage (31.2%
at Day 26 p.i., six days after the second therapy cycle), but it did not follow a continuous increasing
trend during the whole tumor development. In fact, it experienced a decrease during Days 28–31 p.i.
(TRI 11.7% and 13.9%, respectively) and a further increase (44.1% at Day 34 p.i., nine days after the
third therapy cycle), when the mouse was euthanized for histopathological validation. The interval
between the two TRI peak values was of eight days.
Other examples of IR cases can be found in the Supplementary Material. For example, in case
C975 (Figure S3A), TRI increase was first observed at Day 20 p.i., just after the second therapy cycle,
with further increase at 26 p.i. (TRI = 40.3%), six days after the second therapy cycle. In cases C1023
and C1026 (Figure S3B,C), TRI start increasing at Day 18 p.i., after the first therapy cycle with further
increases (35.8% and 38.9%, respectively); at Day 23 p.i., four days after the second therapy cycle;
and eight days after the first cycle. These TRI increases were in the same time frame as in case C1022.
Nosological images acquired for IR cases are also shown in the aforementioned figures. In general,
green responding pixels started to be observed in Grid 1 in all IR cases and then “spread” to the
remaining grids (with a predominance in the upper grids: Grid 1 and Grid 2). Accordingly, there was
a variation in the response level in different grids taking into account the detection of green pixels,
with higher TRI values being found in the upper grids.
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Figure 1. Graphical representation of the tumor volume evolution (in mm3, black line, left axis), and the 
percentage of responding “green” pixels obtained after application of source analysis to MRSI data 
acquired in the multi-slice set as in [13] (in percent, green line, right axis). The green shaded columns 
indicate TMZ administration periods. For chosen time points, the evolution of the nosological images 
obtained with the semisupervised source extraction system is shown in four columns of color coded 
grids, superimposed to the T2w-MRI for each slice (color coding as follows: blue pixels: normal 
parenchyma, red pixels: non responding, green pixels: responding). Green brackets indicate TMZ 
administration periods. (A) Corresponds to the IR case C971, green pixels were observed first at Day 23 
p.i., increasing until 32.2% at Day 26 p.i., when tumor growth arrest was observed. Then, TRI decreased: 
11.7% at Day 28 p.i. and 13.9% at Day 31 p.i., followed by a new increase up to 44.1% at Day 34 p.i. (B) 
Corresponds to the IR case C1022, only red tumor pixels were observed in MRSI measurements until 
Day 23 p.i., tumor volume decrease was observed and green pixels were observed in Grids 1 and 2 (TRI 
= 46.5%). (C) Corresponds to the LR case C979, green pixels were observed only in Grid 1 at Days 13 p.i., 
16 p.i. and 19 p.i. (TRI = 6.3%, 5.2%, 3.3%, respectively), tumor growth arrest was not observed. (D) 
Corresponds to the LR case C981, green pixels were observed only in Grid 1 at Days 13 and 16 p.i. At 
Day 23 p.i., green pixels were observed in Grids 1 and 2 (TRI = 21.5%). 
Figure 1. Graphical representation of the tumor volume evolution (in mm3, black line, left axis), and
the percentage of responding “green” pixels obtained after application of source analysis to MRSI
data acquired in the multi-slice set as in [13] (in percent, green line, right axis). The green shaded
columns indicate TMZ administration periods. For chosen time points, the evolution of the nosological
images obtained with the semisupervised source extra ti n system i shown in four co umns of color
coded grids, supe impos d to the T2w-MRI fo ach slice (col r coding as follows: blue pix ls: normal
parenchyma, red pixels: non responding, green pixels: respo ding). Green brackets indicate TMZ
administration periods. (A) Corresponds to the IR case C971, green pixels were observed first at Day 23
p.i., increasing until 32.2% at Day 26 p.i., when tumor growth arrest was observed. Then, TRI decreased:
11.7% at Day 28 p.i. and 13.9% at Day 31 p.i., followed by a new increase up to 44.1% at Day 34 p.i.
(B) Corresponds to the IR case C1022, only red tumor pixels were observed in MRSI measurements
until Day 23 p.i., tumor volume decrease was observed and green pixels were observed in Grids 1 and
2 (TRI = 46.5%). (C) Corresponds to the LR case C979, green pixels were observed only in Grid 1 at
Days 13 p.i., 16 p.i. and 19 p.i. (TRI = 6.3%, 5.2%, 3.3%, respectively), tumor growth arrest was not
observed. (D) Corresponds to the LR case C981, green pixels were observed only in Grid 1 at Days 13
and 16 p.i. At Day 23 p.i., green pixels were observed in Grids 1 and 2 (TRI = 21.5%).
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LR cases: (C979 and C981) did not respond to therapy with TMZ and they had to be euthanized
due to welfare parameters (see Table S2) at Day 19 p.i. (their body weight loss was higher than
20% compared to the day pre cell injection, C979: 51.55% and C981: 54.22%, before starting the
second therapy cycle). The mean TRI value of these two cases was 13.4 ± 14.3%. In Figure 1C,D,
the relationship between tumor volume and TRI evolution as well as nosological images for cases C979
and C981 are shown.
Very few green responding pixels were observed in the nosological images of case C979 and only
in the first grid (TRI = 3.3% at the euthanasia day). In case C981, green pixels were observed first in
Grid 1 and at the euthanasia day in Grids 1 and 2, but TRI value was higher than case C979, reaching a
value of 21.5%.
2.1.2. Case C974: Tracking the Evolution of an IR Case along Time
This was a case for which euthanasia was not performed at an intermediate tumor evolution
point according to TRI for further histopathology analysis and validation. Indeed, the tumor was
allowed to evolve until endpoint in order to assess TRI changes all along the tumor growth curve.
The tumor volume evolution and its relationship with TRI, as well as the corresponding nosological
images obtained, are shown in Figure 2. The TRI started increasing at Day 18 p.i., three days after
finishing the first therapy cycle, reaching a value of 41.4% at Day 20 p.i. (just after finishing the second
cycle). At this particular moment, although TRI values would meet criteria for classification as IR,
the 21% increase in tumor volume would not agree with “stable disease” according to RECIST criteria.
Then, from Day 20 to Day 31 p.i., volume growth arrest was observed (“stable disease” stage by RECIST
criteria), with maximum volume variation of 11.2% regarding previous measurements. During this
period of growth arrest, a cyclical pattern in TRI values was observed, as follows: TRI value decreased to
11% at Day 22 p.i. (between cycles 2 and 3), then increased again reaching a value of 36.8% at Day 26 p.i.
(one day after finishing the third therapy cycle), moment at which criteria for IR would be accomplished
for this case. Further TRI decreases to 11.7% and 0% were seen at Days 28 and 31 p.i. respectively.
Finally, progressive disease stage by RECIST criteria was observed between Days 34 p.i. and 37 p.i.
(the last measurement, in which tumor volume increased 29.9% and 73.9% regarding the previous
measurements), and TRI during this period also increased to 21.1% and 52.1% values respectively. This
mouse died during MRI acquisition at Day 40 p.i. During this period, body weight loss (compared to
the body weight observed at the day of cell injection) was of 7.3% at Day 34 p.i. and 33% at Day 40 p.i.,
in agreement with frank disease progression.
In the nosological images, green pixels were observed first in the upper grid, as in the other IR
cases. It is worth noting that the TRI high peaks were observed 5–6 days after the first and second
therapy cycle.
Control cases: Tumor volumes of four control mice (C1109, C1110, C1111 and C1112) are shown in
Figure 3. These mice were studied with multi-slice MRSI acquisition (a single measurement, carried
out at the same day these animals were euthanized), and TRI was also calculated (average TRI value
for all cases was of 6.2 ± 2.8%). In case C1109, no green pixels were observed. However, green
responding pixels were also found in the other control cases: in case C1110, a total of six green pixels
were observed after analyzing all grids (TRI = 3.5%); in case C1111 only three pixels were observed
(TRI = 1.9%); and in case C1112, green pixels were observed in Grids 1 and 2 (TRI = 19.3%).
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Figure 2. Graphical representation of the tumor volume evolution (in mm3, black line, left axis), and 
the percentage of responding “green” pixels obtained after source analysis of MRSI data acquired in 
the multi-slice set as in [13] (in percent, green line, right axis) for case C974 (IR case). The green shaded 
columns indicate TMZ administration periods. For chosen time points, the evolution of the 
nosological images obtained with the semisupervised source extraction system is shown in four 
columns of color coded grids, superimposed to the T2w-MRI for each slice. Green brackets indicate 
TMZ administration periods. A cyclical pattern of response was observed, marked by the red arrows 
in the graphical representation. 
Figure 2. Graphical representation of the tumor volume evolution (in mm3, black line, left axis),
and the percentage of responding “green” pixels obtained after source analysis of MRSI data acquired
in the multi-slice set as in [13] (in percent, green line, right axis) for case C974 (IR case). The green
shaded columns indicate TMZ administration periods. For chosen time points, the evolution of
the nosological images obtained with the semisupervised source extraction system is shown in four
columns of color coded grids, superimposed to the T2w-MRI for each slice. Green brackets indicate
TMZ administration periods. A cyclical pattern of response was observed, marked by the red arrows
in the graphical representation.
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Figure 3. Tumor volume evolution (in mm3, black line) of untreated, control cases (C1109, C1110, 
C1111 and C1112). Only one multi-slice MRSI measurement was carried out in these cases. Red arrows 
point to the nosological images obtained with the source analysis system (four columns of color coded 
grids, superimposed to the T2w-MRI for each slice). TRI values obtained for each case were: 0% 
(C1109), 3.5% (C1110), 1.9% (C1111) and 19.3% (C1112). 
2.2. Group B: Therapy Response in Cases Starting Therapy with Tumor Volume 3–5 mm3: Finding High 
Response (HR) Cases 
As no HR cases were found in the first part of the experiment, the objective of this second part 
of the study was to introduce modifications in the therapy protocol in order to increase the probability 
of finding HR cases. For this, therapy administration started when tumor size was between 2.6–5.2 
mm3, disregarding the day p.i. of the tumors. 
From 15 mice which were followed up by MRI, 11 of them started therapy administration at Day 
7 p.i., whereas the other four mice started therapy at Days 9, 11, 13 and 15 p.i., respectively. The mean 
tumor size of these cases at the starting therapy day was of 3.8 ± 0.8% mm3. From these 15 mice, only 
two (C1100 and C1108) presented measurable decrease in tumor volume (5.9% and 12.0%, 
respectively) compared to the previous day of measurement, which was a criterion set by us to start 
the multi-slice MRSI acquisitions. During follow up, these two cases met the requirements for being 
classified as HR cases (TRI > 65% and volume decrease respect the previous day of measurement). 
TRI and other parameters of these cases are shown in Section 2.4. The mean TRI value found in HR 
cases was 68.2 ± 2.8%. Evolution of tumor volume and nosological images of C1100 and C1108 are 
shown in Figure 4. 
Figure 3. Tumor volume evolution (in mm3, black line) of untreated, control cases (C1109, C1110, C1111
and C1112). Only one multi-slice MRSI measurement was carried out in these cases. Red arrows point
to the nosological images obtained with the source analysis system (four columns of color coded grids,
superimposed to the T2w-MRI for each slice). TRI values obtained for each case were: 0% (C1109),
3.5% (C1110), 1.9% (C1111) and 19.3% (C1112).
2.2. Group B: Therapy Response in Cases Starting Therapy with Tumor Volume 3–5 mm3: Finding High
Response (HR) Cases
As no HR cases were found in the first part of the experiment, the objective of this second part of
the study was to introduce modifications in the therapy protocol in order to increase the probability of
finding HR cases. For this, therapy administration started when tumor size was between 2.6–5.2 mm3,
disregarding the day p.i. of the tumors.
From 15 mice which were followed up b MRI, 11 of them started therapy administration at
Day 7 p.i., whereas the other four mice started therapy at Days 9, 11, 13 and 15 p.i., respectively.
The mean tumor size of these cases at the starting therapy day was of 3.8 ± 0.8% mm3. From these
15 mice, only two (C1100 and C1108) presented measurable decrease in tumor volu e (5.9% and 12.0%,
respectively) compared to the previous day of measurement, which was a criterion set by us to start
the multi-slice MRSI acquisitions. During follow up, these two cases met the requirements for being
classified as HR cases (TRI > 65% and volume decrease respect the previous day of measurement). TRI
and other parameters of these cases are shown in Section 2.4. The mean TRI value found in HR cases
was 68.2 ± 2.8%. Evolution of tumor volume and nosological images of C1100 and C1108 are shown
in Figure 4.
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Figure 4. Graphical representation of the tumor volume evolution (in mm3, black line, left axis), and 
the percentage of responding “green” pixels obtained after source analysis of MRSI data acquired in 
the multi-slice set as in [13] (in percent, green dots, right axis) of HR cases. The green shaded columns 
indicate TMZ administration periods. For chosen time points, the evolution of the nosological images 
obtained with the semisupervised source extraction system is shown, superimposed to the T2w-MRI 
for each slice. The number of grids (3 or 4) depended of the coverage of the tumor: if tumor was totally 
covered with three grids, no additional grids were acquired. (A) Corresponds to the case C1100: green 
pixels were observed in Grids 1 and 2 with a TRI = 36.8% at Day 21 p.i. during tumor growth arrest. 
Then at Day 26 p.i., tumor volume decreased and a TRI of 61.8% was observed. (B) Corresponds to 
the case C1108: green pixels were observed in Grids 1 and 2 with a TRI = 70.3% when tumor volume 
decrease was observed. 
For case C1100, therapy administration started at Day 7 p.i., when tumor volume was 3.0 mm3. 
This mouse was explored by MRI until Day 17 p.i. (six days after finishing the first therapy cycle), 
when a 7.1% decrease in volume was observed compared to the previous measurement. From Day 
17 p.i. to Day 21 p.i., tumor growth arrest was observed in MRI measurement. At Day 21 p.i., a 0.6% 
of volume decrease was detected and a multi-slice MRSI measurement was performed and the 
calculated TRI was 36.8%. The next measurement took place at Day 26 p.i. when a TRI of 61.6% was 
detected and a most clear decrease in volume was observed with respect to the previous 
measurement (5.9%). The mouse was then euthanized for histopathological validation. In the 
nosological images (Figure 4A), at the first day of MRSI acquisition, green pixels were observed in 
the first two upper grids and in the last day of measurement, green pixels were observed in Grids 1, 
2 and 3 (in the fourth grid, the tumor could not be properly segmented with our analysis, probably 
due to the small tumor area found in this grid, composed mostly by normal/peritumoral tissue). 
Regarding case C1108, therapy administration started at Day 15 p.i., when tumor volume was 
2.9 mm3. This mouse was explored by MRI until Day 29 p.i. (five days after finishing the second 
therapy cycle, when a 12% decrease in volume was observed compared to the previous 
measurement). The value found for TRI that day was 70.3% and the mouse was euthanized for 
histopathological validation. In nosological images (Figure 4B), green pixels were observed in Grid 1 
and Grid 2 (in Grid 3, the tumor could not be segmented, as previously mentioned for case C1100). 
Body weight loss of both cases was less than 20% the day euthanasia was performed (C1100: 9% 
and C1108: 11.5%). Accordingly, significant differences (p < 0.05) were observed in body weight 
Figure 4. Graphical representation of the tumor volume evolution (in mm3, black line, left axis), and
the percentage of responding “green” pixels obtained after source analysis of MRSI data acquired in
the multi-slice set as in [13] (in percent, green dots, right axis) of HR cases. The green shaded columns
indicate TMZ administration periods. For chosen time points, the evolution of the nosological images
obtained with the semisupervised source extraction system is shown, superimposed to the T2w-MRI
for each slice. The number of grids (3 or 4) depended of the coverage of the tumor: if tumor was totally
covered with three grids, no additional grids were acquired. (A) Corresponds to the case C1100: green
pixels were observed in Grids 1 and 2 with a TRI = 36.8% at Day 21 p.i. during tumor growth arrest.
Then at Day 26 p.i., tumor volume decreased and a TRI of 61.8% was observed. (B) Corresponds to
the case C1108: green pixels were observed in Grids 1 and 2 with a TRI = 70.3% when tumor volume
decrease was observed.
For case C1100, therapy administration started at Day 7 p.i., when tumor volume was 3.0 mm3.
This mouse was explored by MRI until Day 17 p.i. (six days after finishing the first therapy cycle),
when a 7.1% decrease in volume was observed compared to the previous measurement. From Day 17
p.i. to Day 21 p.i., tumor growth arrest was observed in MRI measurement. At Day 21 p.i., a 0.6% of
volume decrease was detected and a multi-slice MRSI measurement was performed and the calculated
TRI was 36.8%. The next measurement took place at Day 26 p.i. when a TRI of 61.6% was detected
and a most clear decrease in volume was observed with respect to the previous measurement (5.9%).
The mouse was then euthanized for histopathological validation. In the nosological images (Figure 4A),
at the first day of MRSI acquisition, green pixels were observed in the first two upper grids and in the
last day of measurement, green pixels were observed in Grids 1, 2 and 3 (in the fourth grid, the tumor
could not be properly segmented with our analysis, probably due to the small tumor area found in
this grid, composed mostly by normal/peritumoral tissue).
Regarding case C1108, therapy administration started at Day 15 p.i., when tumor volume was
2.9 mm3. This mouse was explored by MRI until Day 29 p.i. (five days after finishing the second
therapy cycle, when a 12% decrease in volume was observed compared to the previous measurement).
The value found for TRI that day was 70.3% and the mouse was euthanized for histopathological
validation. In nosological images (Figure 4B), green pixels were observed in Grid 1 and Grid 2 (in Grid
3, the tumor could not be segmented, as previously mentioned for case C1100).
Metabolites 2017, 7, 20 9 of 29
Body weight loss of both cases was less than 20% the day euthanasia was performed (C1100: 9% and
C1108: 11.5%). Accordingly, significant differences (p < 0.05) were observed in body weight evolution
between HR and IR cases, between HR and LR cases and between IR and LR cases (see also Figure S2).
2.3. Metabolic Pattern Contributing to Responding and Non-Responding (Red and Green) Areas Detected in
MRSI Studies of the Investigated Mice
Different metabolites have been described to contribute to the spectral pattern of preclinical
glioblastoma [13,18,22–29] and some of them are listed in Table 1, being also observed in cases
analyzed in this study. Figure 5 shows examples of average spectra extracted from blue, red and green
zones of a HR case (C971), whereas Figure S4 show examples of average spectra from red and green
zones in comparison with the sources extracted from treated and untreated cases, reported in [13].
It is worth mentioning that the changes observed in the whole metabolic pattern, rather than isolated
changes in few metabolites, is what allows the semi-supervised source extraction system to classify
MRSI voxels in different classes (normal brain, responding tumor and non-responding tumor) [13].
Table 1. List of the main metabolites contributing to the spectral pattern recorded in tumor/peritumoral
MRSI of responding and non-responding mice, with the corresponding approximate ppm position.
Major contributions are shown in italic, although other signals can also be identified and are also
contributing to the recorded pattern. Metabolite assignments according to [18,22–32].
Metabolite ppm
Mobile Lipids + Macromolecules 0.90
Mobile Lipids + Lactate 1.33
Alanine 1.47
N-acetyl-aspartate + N-acetyl containing compounds + Mobile lipids 2.02
Glutamate + glutamine 2.10 − 2.40 + 3.80
PUFA (Mobile Lipids) 2.80
GABA 3.00
Total Creatine 3.03
Choline-containing compounds 3.21
Scyllo-inositol 3.34
Taurine 3.42
Myo-inositol + glycine 3.55
Lactate 4.10
The main differences between normal brain parenchyma and tumor areas (blue vs. green/red
areas) were: higher choline/creatine (Cho, 3.21/Cre, 3.03 ppm) ratios, higher mobile lipids
(ML, 0.9 and 1.3 ppm) and lactate (Lac, 1.3 ppm and 4.1 ppm) peak intensities in tumor areas, as well
as lower N-acetyl-aspartate (NAA/NAc, 2.02 ppm) signal, already described by us in [18]. The zones
classified as “normal brain parenchyma” by the source extraction approach presented the expected
features, such as lower ML and ML/Lac signals in comparison with tumors, and a ca. 1:1 ratio for Cho
and Cre (see [26] for more examples of control spectra in mice brain).
Although the responding and non-responding spectra (which are present in green and red areas
respectively) could seem quite similar, relevant differences between them are sampled by the source
analysis especially related to polyunsaturated fatty acids in ML (PUFA, 2.8 ppm), as already described
by [18,30]. Other minor contributions are Lac (4.1 ppm), glutamine plus glutamate and alanine
(Glx + Ala, 3.8 ppm) and myo-inositol and glycine (Ins + Gly, both seen at 3.55 ppm).
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Figure 5. Example of mean spectra extracted from the MRSI grid of a treated case (HR case
C971: Grid 1, Day 34 pi): (A) mean spectra of responding area (n = 26); (B) mean spectra of
non-responding area (n = 35); and (C) mean spectra of normal brain parenchyma area (n = 39).
Some of the main metabolites contributing to different patterns of response to therapy are shown:
mobile lipids 0.9 + macromolecules (ML, MM, 0.9 ppm), m bile lipids 1.3 + lactate (ML/Lac, .3 ppm),
N-acetyl-aspartate nd N-acetyl group containing compounds (NAA and NAc, 2.02 ppm) (see also [31]),
glutamate + glutami e (Glx, 2.1–2.4 ppm) polyunsaturated fatty acids i mobile lipids (PUFA, 2.8 ppm),
total creatine (Cre, 3.03 ppm), choline-containing compounds (Cho, 3.21 ppm), myo-inositol + glycine
(Ins + Gly, 3.55 ppm), glutamine + glutamate (Glx, 3.8 ppm, which is also partially contributed by
alanine), and lactate (Lac, 1.3 and 4.1 ppm).
2.4. Histopathology Validation
Cases used for histopathological validation were, according to TRI response: two HR cases (C1100
and C1108), three IR cas s (C971, C1022 and C1026), one LR c se (C979) and two Control cases (C1110
and C1111).
Haematoxylin/Eosin morphology analysis: different cell morphol gy (aberrant large a d giant
cells and multinucleated cells) and presence of large acellular spaces were observed in samples of
treated mice, in comparison to non treated mice, for which those characteristics were not observed.
In Figure 6, examples of histopathological preparations with Ki67 immunostaining, corresponding to
green pixels and red pixels areas in tumors, are shown for representative cases of each class (C1110,
C979, C971 and C1108). Ki67 immunostainings and nosological images of remaining cases evaluated
by histopathology, C1111, C1022, C1026 and C1100, are shown in Figure S5.
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nuclei and scanty cytoplasm without any giant cells visible. (B) LR case, C979: in this case, Ki67 
positive cells were also observed (64.8 ± 7.3%) but with less cellular density due to presence of large 
acellular spaces in comparison with the control case. (C) IR case C971 presented lower Ki67 
immunostaining (22.0 ± 17.2%) than control and LR cases, with presence of giant cells with several 
nuclei (black arrows), and also acellular spaces. No significant differences were observed for Ki67 
between red and green areas from nosological images of this case, although the trend to higher Ki67 
in red areas is maintained (Ki67 for red areas 25.7 ± 17.0% and Ki67 for green areas 17.2 ± 16.8%). (D) 
HR case C1108, with an average Ki67 of 79.3 ± 10.1%, although it is worth noting that HR cases present 
lower number of total tumoral cells per field in comparison with IR cases (57.1 ± 16.9 and 86.7 ± 63.9 
cells/field respectively), which could have an influence in the final result of Ki67% calculation. Still, 
acellular areas and giant cells (black arrows) were also observed. See Discussion Section for a possible 
explanation with respect to apparently high Ki67 values in green nosological image regions. 
Ki67 analysis: Comparison of responding and non-responding zones: green and red areas of the 
nosological images, disregarding the case categorization, showed a trend, with green zones having 
lower Ki67 values (42.9 ± 32.6%, n = 50 fields) than red zones (52.9 ± 25.1%, n = 121 fields) (see Figure 
7). Significant differences were found with Mann–Whitney’s U test (p < 0.05), although there is 
considerable dispersion within the data. The Ki67% value found for red zones of treated cases was 
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same case), the obtained results varied depending on the case: IR cases presented either statistical 
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whereas HR cases did not present statistical significance. 
Figure 6. Ki67 immunostainings (40×magnification, the scale bar corresponds to 50 µm) in histological
areas corresponding to red or green regions in nosological images, from different grids of chosen cases.
The yellow rectangles in the nosological image identify the approximate origin of the histopathological
preparations shown. The nuclei of i67 positive cells are staine i brown. (A) Control case C1110,
with glob l Ki67 of 63.9 ± 13.0% and a highly ense c llular p pulat on showing a typical tumoral
morphology with small to medium-sized polygonal or irregular ells with rounded nuclei and
scanty cytoplasm without any giant cells visible. (B) LR case, C979: in this case, Ki67 positive cells
were also observed (64.8 ± 7.3%) but with less cellular density due to presence of large acellular
spaces in comparison with the control case. (C) IR case C971 presented lower Ki67 immunostaining
(22.0 ± 17.2%) than control and LR cases, with presence of giant cells with several nuclei (black arrows),
and also acellular spaces. No significant differences were observed for Ki67 between red and green
areas from nosological images of this case, although the trend to higher Ki67 in red areas is maintained
(Ki67 for red areas 25.7 ± 17.0% and Ki67 for green areas 17.2 ± 16.8%). (D) HR case C1108, with an
average Ki67 of 79.3 ± 10.1%, altho gh it is worth noting that HR cases present lower number of total
tumoral ce ls per field in comparison with IR cases (57.1 ± 16.9 and 86.7 ± 63.9 cells/field respectively),
which could have an influence in the final result of Ki67% calculati n. Sti l, acellular areas and giant
cells (black arrows) were also observed. See Discussion Section for a possible explanation with respect
to apparently high Ki67 values in green nosological image regions.
Ki67 analysis: Comparison of responding and non-responding zones: green and red areas of the
nosological images, disregarding the case categorization, showed a trend, with green zones having
lower Ki67 values (42.9 ± 32.6%, n = 50 fi lds) than r d zones (52.9 ± 25.1%, n = 121 fields)
(see Figure 7). Significant diff rence were found with Mann–Whitney’s U test (p < 0.05), although
there is considerable dispersion within the data. The Ki67% value found for red zones of treated cases
was not significantly different from values obtained in red zones of control untreated cases. Analyzing
green and red zones in a case-by-case study (i.e., comparing Ki67 for red and green zones within the
same case), the obtained results varied depending on the case: IR cases presented either statistical
significance (p < 0.05, C1022) (Figure 8) or a trend towards significance (0.15 > p > 0.05, 1026, C971),
whereas HR cases did not present statistical significance.
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Figure 8. Example of the histopathological validation of a nosological image of Grid 2 of the case 
C1022 (IR case). (A) Nosological image obtained from Grid 2 of the case C1022 superimposed to the 
T2w-MRI. Both green and red zones could be distinguished within the tumor, showing a heterogeneous 
pattern of response. (B) Ki67 immunostaining colocalized with the Grid 2, in which the red and green 
areas from the nososological image have been manually drawn over the tumor (shown in red and green 
dashed lines). One representative field has been selected in each area (yellow rectangles have the same 
area). (C) Magnification (40×) of the yellow field from the green area, with an average Ki67% value of 
23.9%, and black arrows pointing to Ki67 positive cells. (D) Magnification (40×) of the yellow field from 
the red area, with a Ki67% value of 85%, and black arrows pointing to Ki67 positive cells. 
Taking into account these results, we wondered whether green and red zones could have 
significantly different Ki67 values depending on the classification of the case according to TRI level 
(e.g., all green zones of IR cases vs. all green zones of HR cases). For IR cases, we found Ki67 values 
of 52.0% for red zones and 21.1% for green zones, whereas cases classified as HR presented values of 
84.1% for red zones and 77.7% for green zones. This would suggest that although there is indeed a 
correlation between a responding/non-responding pattern and its Ki67 immunostaining, the absolute 
values could be quite different between intermediate response and high response cases, which could 
be at least partially explained due to different cellularity between these cases. 
The global Ki67% for each case was also analyzed taking into account the Ki67 values found for all 
slices of a given case, which would reflect an average proliferative state of the whole tumor. Global 
Ki67 data are shown in Table 2. Still, higher global values were observed in control cases than in 
treated cases as a whole (Figure S6A, 68.6%, n = 40 fields vs. 52.6%, n = 139 fields respectively). 
Figure 7. Graph bar of mean ± SD of Ki67% values found in green and red areas from nosological
images of all studied cases. Significant differences (p < 0.05 with Mann–Whitney’s U test) were
found between them, with higher values in red (59.9 ± 25.1%) areas in comparison with green areas
(42.9 ± 32.6%).
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Figure 8. Example of the histopathological validation of a nosological image of Grid 2 of the case C1022
(IR case). (A) Nosological image obtained from Grid 2 of the case C1022 superimposed to the T2w-MRI.
Both green and red zones could be distinguished within the tumor, showing a heterogeneous pattern
of response. (B) Ki67 immunostaining colocalized wi the Grid 2 in which the red and gre n areas
from the nososo ogical image have been manually drawn over the tumor (shown in red and green
dashed lines). One representative field has be n selected in each area (yellow rectangles have the same
area). (C) Magnification (40×) of the yellow field from the green area, with an average Ki67% value of
23.9%, and black arrows pointing to Ki67 positive cells. (D) Magnification (40×) of the yellow field
from the red area, with a Ki67% value of 85%, and black arrows pointing to Ki67 positive cells.
Taking into account these results, we wondered whether green and red zones could have
significantly different Ki67 values depending on the classification of the case according to TRI level
(e.g., all green zones of IR cases vs. all gree zon s of HR cases). For IR ca es, we found Ki67 values of
52.0% for red zones and 21.1% for green zo es, whe as cas clas ified as HR presented values of
84.1% for red zon s and 77.7% for gr en zones. This would suggest that although there is in eed a
correlation between a responding/non-responding pattern and its Ki67 immunostaining, the absolute
values could be quite different between intermediate response and high response cases, which could
be at least partially explained due to different cellularity between these cases.
The global Ki67% for each case was also analyzed taking into account the Ki67 values found for all
slices of a given case, which would reflect an average proliferative state of the whole tumor. Global
Ki67 data are shown in Table 2. Still, higher global values were observed in control cases than in
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treated cases as a whole (Figure S6A, 68.6%, n = 40 fields vs. 52.6%, n = 139 fields respectively).
Significant differences were found with Mann–Whitney’s U test (p < 0.05). Regarding treated cases,
higher global Ki67 values were observed in LR cases (64.8 ± 7.3%) than in IR cases (41.9 ± 32.2%),
as expected (Figure S6B). However, surprisingly, HR cases presented a value higher than expected and
a possible explanation, which will be further elaborated in the Discussion Section, can be related to the
lower cellularity observed in these cases and the different cell volume observed in treated cases with
intermediate or high response, as mentioned before.
Table 2. Results of Ki67 percentage ± SD of fields corresponding to green and red pixels in nosological
images, as well as the global percentage of Ki67 for the studied cases. Percentage of TRI and its
classification by TRI criteria are also shown. n.a. = not available (the low number of green pixels
observed in the case C979 (seven in Grid 1 and four in Grid 2), did not allow to confidently establish a
field for corresponding histopathology evaluation in that tumor region).
Case Ki67%± SD(Green Fields)
Ki67%± SD
(Red Fields)
Ki67%± SD
(Global) TRI%
Classification
by TRI Criteria
C971 17.2 ± 16.8 25.7 ± 17.0 22.0 ± 17.2 44.1 Intermediate
C1022 19.0 ± 20.9 54.9 ± 32.6 * 42.5 ± 33.5 46.5 Intermediate
C1026 53.5 ± 30.3 73.0 ± 26.8 66.0 ± 39.1 38.9 Intermediate
C979 n.a. 64.8 ± 7.3 64.8 ± 7.3 3.3 Low
C1100 82.9 ± 4.6 92.5 ± 0.6 82.2 ± 7.7 66.3 High
C1108 75.1 ± 9.5 75.8 ± 0.2 79.3 ± 10.1 70.3 High
C1110 n.a. 63.9 ± 13.0 63.9 ± 13.0 0 Control
C1111 n.a. 73.3 ± 6.4 73.3 ± 6.4 0 Control
* = significant differences in Ki67% between red and green areas for this case.
Significant differences were observed for Ki67 (p < 0.05) between groups of cases classified by
their TRI response level (LR cases, IR cases, and IR cases) (Figure S6B). The Ki67% of the different
groups classified by TRI and their TRI values are also summarized in Figure 9.
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cases showed similar mean values of TRI 42.1 ± 5.6% and Ki67: 43.5 ± 22.0%, presenting also a very high 
dispersion as well. HR cases showed higher values of TRI (as expected, 68.3 ± 2.8%) but unexpectedly 
high Ki67 values (77.8 ± 6.3%). Boxplot: The limits of the box represent quartiles 1 (Q1) and 3 (Q3) of the 
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Figure 9. Boxplot of global percentage of Ki67 (white boxes) and percentage of TRI values (striped boxes)
of each MRSI grid of different groups of cases classified by TRI response and analyzed by histopathology.
Control and LR cases with low values of TRI (2.7 ± 1.1% for control cases and 3.3 ± 0% for LR cases)
showed higher Ki67 values (71.6 ± 10.9% for control cases and 64.8 ± 0% for LR cases). IR cases
showed similar mean values of TRI 42.1 ± 5.6% and Ki67: 43.5 ± 22.0%, presenting also a very high
dispersion as well. HR cases showed higher values of TRI (as expected, 68.3 ± 2.8%) but unexpectedly
high Ki67 values (77.8 ± 6.3%). Boxpl t: The limits of the box r present quartiles 1 (Q1) and 3 (Q3)
of the distribution, the central line correspon to the median (quartile 2). The whiskers symbolize
the maximum and minimum values in each distribution. Outliers (values higher than 1.5 × IQR,
interquartile range, obtained by difference of Q3 and Q1) are represented with round symbols.
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3. Discussion
3.1. Multi-Slice MRSI and TRI for Therapy Response Level Evaluation
MRSI acquisitions allowed us to obtain differential metabolomic patterns from treated and control
tumors. Although it is true that other authors have also applied MRSI techniques in order to assess the
effect of therapy in brain tumors [7,8,33,34], they were mainly focused in some particular signals or
ratios (such as quantitation of NAA, Cho, Cr or ratios between them). These ratios have proved useful
in our model [18] only when using single voxel MRS data, but did not succeed to produce robust
discrimination when individual spectra from MRSI grids classified as responding and non-responding
were used for the calculation (data not shown). This probably suggests that there is not a single change
or a set of few changes/ratios which could fully distinguish a responding from a non-responding zone.
In this sense, the source-based approach technique applied to MRSI data in this study takes into account
the whole set of possible metabolic changes in the spectral pattern and can handle the information in a
way that may not be straightforward to perform after standard quantification, for example with the
LCModel [35]. Table 1 lists the main metabolites, lipids and macromolecules thought to contribute to
the spectral patterns recorded. The detection of signals at 2.8 ppm, compatible with presence of PUFA
is in agreement with authors in [30], who reported similar signals in their preclinical model, as early as
two days after therapy with ganciclovir, being indicative of apoptosis.
After acquiring MRSI data from our mice, nosological images were then generated to follow-up
the evolution of tumor response to treatment. Previous studies from our group using MRSI-based
source analysis from a single slice allowed us to distinguish between responding and non-responding
cases [13], with metabolomics pattern derived changes preceding the anatomical derived information
provided by MRI in several instances. However, the use of a single slice, ignoring the response level
taking place in other tumor areas, could prevent us to gather relevant information, as GBM is widely
accepted to be highly heterogeneous [36]. The multi-slice MRSI technique used in this study has
allowed us to obtain nosological images from different areas of the investigated tumors, unraveling
heterogeneous response levels that we were unable to see with the single slice examination. In work
presented in [13], several treated cases presented a response level (when recalculated for the presently
proposed TRI index) close to 100% (mean TRI = 92.9 ± 8.2%, n = 8) whereas in the present work
with whole tumor examination, the maximum value achieved was of 70.3% and the mean ± SD of
all treated mice was 40.8 ± 20.5%. Still, we observed that not all MRSI slices had the same response
level after treating mice with TMZ, with upper more dorsal slices presenting higher levels of TRI
(53.0 ± 28.4%) than lower more ventral ones (8.6 ± 20.0%) (p < 0.05). Once the TRI parameter was
calculated, it allowed us to quantify the evolution of response to treatment and also to classify cases in
different arbitrary categories. It is worth noting that the generation of nosological images presents
some limitations, namely: highly heterogeneous or hemorrhagic zones could result in poor quality
MRSI spectra, preventing the system to classify them correctly. In addition, the smallest tumor correctly
segmented had a volume of 18.4 mm3, which should be taken into account when interpreting data of
apparently non-responding or normal parenchyma regions.
3.2. Classification of TMZ-Treated Mice after TRI Calculation and Evolution of TRI Values
Treated mice were classified into different groups, as explained in results Sections 2.1 and 2.2
and Table 2. The first part of the study only produced LR and IR cases, and a modification of the
initial protocol was needed in order to obtain cases fulfilling preset criteria for HR cases. The fact
that some cases presented only partial response to therapy was seen in our previous work [13] with
one single MRSI slice in cases C418, C527 and C584 (with TRI response now calculated for those
single-slice acquisitions of 21.3%, 60.6% and 49.0%, respectively). However, the detailed subdivision in
“response groups” and heterogeneity observation was only possible after performing a multi-slice MRSI
acquisition, confirming the heterogeneous pattern of response usually seen in GBM. This heterogeneous
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pattern of response has also been reported in other preclinical studies using diffusion-weighted MRI
techniques [37] and using PET-MRI techniques in humans [38].
The evolution of TRI in the different cases studied with longitudinal measurements indicated that
increases in TRI corresponded essentially to periods of growth arrest (stable disease stage following RECIST
criteria) and following therapy cycles. Regarding IR cases, the TRI increase was seen around 6.5 ± 1.0
days after the first therapy cycle (n = 4), except in n = 2 cases in which the highest increase was seen six
days after the second therapy cycle. It is worth mentioning that in IR cases (see Figure 1A,B), the first
appearance of the responding pixels preceded the growth arrest observed in MRI acquisitions. On the
other hand, LR cases presented a slightly different evolution: these cases did not show tumor growth arrest
even when they were treated and TRI pixels were first observed during the first therapy cycle (earlier than
in IR cases, see Figure 1C,D). Still, some cases, i.e., C971, seemed to show an oscillating pattern for TRI
(see Figure 1A) in which two peaks of increased TRI (31.2% and 44.1%) were separated by eight days.
The protocol designed for this study was focused in allowing the histopathological validation of
nosological images recorded at certain time points, meaning that mice fulfilling criteria for inclusion
in a response group were euthanized after MRSI acquisition to allow for in vivo/in vitro correlation.
Accordingly, we could not observe the evolution of TRI along the whole treatment period for the
investigated mice. To avoid this restriction, one of those mice (C974) was saved to be followed up
until end-point. In this mouse we could clearly observe a cyclical pattern in TRI values, as opposed to
tumor volume, which remained stable during six days (maximum variation of 11.20% corresponding
to stable disease following RECIST criteria). The TRI presented different values along tumor evolution
(see Figure 2), with the first maximum peak of TRI (41.4%) being observed at Day 20 p.i. (five days
after finishing the first therapy cycle), whereas the second maximum peak of TRI (36.8%) was observed
at Day 26 p.i. (six days after finishing the second therapy cycle). This cyclical observation of TRI peaks
(5–6 days after therapy cycles) was taking place at the same time that tumor volume was indicating
“stable disease” according to RECIST criteria. Then, a last peak of TRI was observed at Day 37 p.i.,
when tumor relapsed (at progressive disease stage). This was 12 days after finishing the last therapy
cycle and the animal died due to tumor mass effect (140.5 mm3). As the objective in this case was not
focused in histopathological validation, no samples of C974 were saved for such analysis.
This cyclical pattern of response was not obvious in other IR cases (C975, C1022, C1023 and
C1026), in which TRI increases were observed during tumor growth arrest, or when tumor growth
arrest started to be observed. However, it is possible that the prompt animal euthanization, when these
TRI increases were observed, could have prevented us to observe further TRI oscillations.
The HR cases were only observed when the protocol was adjusted to start therapy with smaller tumor
volumes (3.7 ± 0.8 mm3). In these, TRI increase was observed five days after the second therapy cycle,
although in these cases the MRSI acquisition was conditioned to tumor volume decrease and no previous
MRSI data was acquired. Finally, LR cases did not respond to therapy and no TRI oscillations were observed.
The reason why these cases were not responding could be due, among other reasons, to individual tumor
resistance to alkylating agents, which is mainly due to overexpression of the MGMT protein, and it is a
major and currently unresolved problem with TMZ therapy [39]. Still, different glioma-initiating cells (GIC)
clones from the same GBM tumor may have different levels of therapy resistance to different therapies,
resulting in a heterogeneous pattern of response to therapy in the same tumor [36]. It was beyond the
scope of our present study to establish whether a correlation between TRI level and overall survival exists
or not. However, from the data gathered, it was clear that the behavior of TRI, as opposed to the relatively
unchanged tumor volume during growth arrest, presented an oscillating pattern with an approximated
frequency around 6.3± 1.3 days (n = 4). See possible explanations for this in Section 3.4.
Intuitive cyclical changes in TRI at stable disease stages could be observed in three longitudinal cases
included in [13]. These cases (C817, C819 and C821) were followed up until endpoint by single slice MRSI.
The mean frequency of these TRI cycles now recalculated (6.3± 2.0 days, n = 3) was very similar to the
one calculated using the multi-slice approach in this work (6.3± 1.3 days). Nonetheless, the representation
of TRI evolution is clearer in cases studied by the multi-slice approach than in single slice MRSI cases.
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3.3. Histopathology Results
Histopathology analysis was conducted for all acquired grids in chosen animals (see Section 2.4) in
order to confirm the results previously described in [13], in which an inverse and significant correlation
between the responding pattern and the proliferation marker Ki67 was found, with green, responding
zones presenting a significantly lower Ki67% value. This histopathological biomarker was also chosen
by other authors in order to estimate therapy response in preclinical brain tumors [40,41] and in human
glioblastoma [42,43].
As can be seen in Figure 7, this trend has been also seen in this work with multi-slice MRSI
acquisition, although the fold change was slightly different (1.4 fold change in this study, compared
to 2.4 fold change obtained in previous studies of our group with one single MRSI slice [13], when
comparing zones with red or green pattern). Although the dispersion of values was really large,
especially within green zones, we have been able to confirm that lower mean values of Ki67 are found
in green zones, whereas higher values are seen in red zones, either from controls or treated tumors.
One of the unexpected findings in this work was that HR cases had the highest calculated Ki67%
values, in disagreement with tumor volume behavior, which was showing signs of volume decrease.
The lower cellularity in investigated fields from those cases, with large acellular spaces between abnormal
giant cells (morphology described by other authors in human glioma treated with radiotherapy [44] and in
human treated sarcoma [45]) could be partially responsible for that. We wondered if analyzing the number
of Ki67 positive cells by mm2 instead of percent tumor cells would be helpful for clarification, and the results
may be seen in Figure S7, in which the number of Ki67 positive cells/mm2 is illustrated. A descending trend
is clearly seen between control (2912.4± 692.7 cells/mm2, n = 2), LR (1799.2± 369.7 cells/mm2, n = 1)
and IR (372.7± 264.7 cells/mm2, n = 3) cases. Regarding HR cases, values found (713.6± 211.5 cells/mm2,
n = 2) were slightly higher than IR cases, but lower than LR and control cases. In addition, significant
differences were found with Mann–Whitney’s U test (p < 0.05) between the groups. This would probably
suggest that the absolute number of Ki67 positive cells for mm2 would not be quite different in IR and HR
cases, but the overall abnormal morphology of the cells as well as tumor behavior and the metabolomics
pattern from MRSI acquisitions are indicating that the response level is higher in HR cases.
Having in mind the different morphology observed in cases under treatment and the effect that
it seemed to produce in Ki67% calculation, we tried to assess the mean cell volume in each group of
cases, as well as the amount of acellular space observed in histopathological slides in order to better
understand which kind of elements would be essentially contributing to the observed MRSI pattern.
For this, we calculated the average volume of Ki67 positive cells present in a representative field of
different cases (n = 8 cases, 2 HR, 1 LR, 3 IR and 2 control) (Figure S8A) as well as the percentage of
acellular space observed (in the same group of cases) (Figure S8B). In Figure S8A, an ascending trend
of increasing cell volume is observed: control cases (372.1 ± 178.8 µm3, n = 50 cells counted), in LR
cases (1867.3 ± 1698.9 µm3, n = 25 cells), in IR cases (6179.9 ± 9855.5 µm3, n = 54 cells) and in HR
cases (8180.6 ± 7608.3 µm3, n = 45 cells). Significant differences were found with Mann–Whitney’s
U test (p < 0.05) between the groups. This could probably distort the Ki67% estimation value if the
calculations are done in the same way for control and responding tumors, because the average cell
volume could be 22 fold higher in an HR case than in a control case, and a given field, accordingly,
will be represented by a lower number of cells. Furthermore, a high number of histological fields with
plenty of acellular space was observed in treated cases, which cannot be neglected either. Regarding
them, in figure S8B an increasing trend in the percentage of acellular space is observed: control cases
presented only 19.1 ± 6.9%, whereas ascending values were observed in treated cases: LR cases with
27.5 ± 8.2%, IR cases with 37.4 ± 11.0% and HR cases 44 ± 15.3% which is almost half of the field.
Significant differences were found with Mann–Whitney’s U test (p < 0.05) between groups.
These acellular spaces are large, irregular and they are usually observed in the central part of
treated tumors, which indicates that they were caused by therapy with temozolomide and not by tissue
fixation and processing. In the case of acellular spaces due to tissue fixation, those spaces are usually
observed in the tumor periphery at the border zone between tumor and normal brain parenchyma.
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Therefore, control (untreated) cases showed smaller cell volumes of Ki67 positive stained cells as
well as much less acellular space than treated cases, resulting in fields with high average cellularity.
On the other hand, in treated cases, the increase in response level (TRI values) was accompanied by
an increase in cell volume (with presence of giant cells) and a higher presence of acellular space in
histological fields. Accordingly, the difference in cell volume and percentage of acellular space in the
evaluated histopathological fields could partially explain why an apparently high Ki67 value is found
in HR cases if a standard percent counting is performed. It may be more adequate to analyze results
the way shown in Figure S7, for which the number of Ki67 stained cells is seen to significantly decrease
between control, LR and IR + HR cases.
To illustrate data used to calculate Figure S8, representative fields of control, LR, IR and HR
cases are shown in Figure 10. In control cases, uniform smaller cells and fewer acellular spaces were
observed than in treated cases. In those treated cases, with higher TRI response levels, cell morphology
changed: giant cells were observed as well as an increase in acellular space (white spaces shown
in Figure 10) was detected.
An interesting additional finding was that in IR and HR cases, small lymphocyte-like cells were
observed (red arrows in Figure 10), which would be compatible with tumor infiltration by lymphocytes,
although further confirmatory work will be needed for a full validation of the extent of this observation.
These lymphocyte-like cells were not observed in LR and control cases.
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Figure 10. Histopathological regions (20× ification) from repr sentativ fields f c ntrol, LR, IR
and HR cases. A higher number of uniform and s all tu oral cells were observed in the control case
in comparison to LR, IR and HR cases. A low number of large tumoral cells were observed in treated
cases (with many of them possibly converting to giant cells in IR and HR cases). Regarding acellular
spaces, in control cases, cells were more densely organized and few such spaces were observed. On the
other hand, in treated cases, especially HR cases, the percentage of acellular space was significantly
higher (see also Figure S8). In IR and HR cases, numerous lymphocyte-like cells (red arrows) and giant
cells (black stars) were also observed.
It is worth stressing that obtaining HR cases was not straightforward and required modifications of
the initially designed protocol. Even when modifications were introduced, and this is one of the important
findings in this study, the metabolomics based analysis of multi-slice MRSI showed that there were in our
hands no 100% responding tumors, reinforcing the idea that GBMs present high heterogeneity, probably
with clonal selection of resistant cells after therapy administration. The use of combined therapeutic
agents, as well as modified ad inistration schedules such as metronomic administration, could be of help,
as promising results have been recently obtained in our group with the same preclinical GBM model [46].
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In this multi-slice study, in which a tridimensional-like reconstruction approach was attempted,
it was possible to establish a relationship between groups of cases with different TRI levels and Ki67
values. The global analysis case by case of multi-slice acquisitions can provide a good estimation of
the response level of the whole tumor probably better than using the single slice approach, which
could provide an overoptimistic outcome. The reason for this being that the slice used for single slice
protocol usually corresponded to the Grid 2 in the multi-slice protocol, and as previously stated, most
of the green pixels, corresponding to the responding pattern were located in Grids 1 and 2. In this
sense, the multi-slice approach provided a more realistic analysis while the inverse correlation found
between TRI and the Ki67 “global” value (see for example Figures S6 and S7) confirmed the findings
from previous work of our group [13].
3.4. A Possible Explanation for the Cyclical TRI Behavior: TMZ Therapy Triggering Immune Response in Host
From previous and present data from our group, TRI has been proven to follow a non-linear
behavior, with an oscillating pattern, which was intuitive in single-slice cases from [13] but became
clear in the multi-slice recordings of mice in this work. This is suggesting that the metabolomic pattern
changes are dynamic and vary along time. They not only vary among different cases, but they vary
inside the same tumor as well, indicating a differential behavior which seems to display an apparent
frequency of ca. 5–7 days. One of the possible explanations for that lies in the mechanism of cell
damage triggered by TMZ. Some authors have described that after alkylating agents (e.g., TMZ)
treatment a recruitment of the host immune system takes place [47,48] which is relevant in the response
to therapy, eventually triggering tumor cell death. Still, it is described in [49] that the whole immune
cycle (see Figure 11) in mice brain usually requires around six days, which agrees with the oscillation
period recorded in this work (see Figure 2). The process includes recognition of local antigens by
dendritic cells (DC), migration to regional lymph nodes, where they present processed tumor-derived
peptides to naïve CD8+ and CD4+ T cells, which leave afterwards lymphoid organs to infiltrate tumor
tissues and exert effector functions, killing tumor cells.
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Figure 11. Scheme of the cycle for immune response against a brain tumor. The whole cycle in mouse brain
is assumed to take around 6–7 days [49]. The malignant cells may release immunogenic signals, after the
chemotherapeutic agent (TMZ) effect on them. These signals attract dendritic cells (DCs) precursors to the
tumor, were they are activated by compromised tumor cells. T en, activated DCs migrate to local lymph
nodes (LN), like dorsal cervical lymph no e for brain, and present processed tumor-d rived p ptides
to naïve T and B-lymphocytes. In case of antigen match, they are then activated to become plasma cells
producing antibodies, CD4+ helper T lymphocytes or CD8+ cytotoxic T lymphocytes (CTLs). Activated
CTLs leave LN to infiltrate brain tumor tissues and exert effector functions [50,51].
Metabolites 2017, 7, 20 19 of 29
All this taken into account suggests that the metabolomics responding pattern could act as a
surrogate biomarker of these immune cell “waves” killing sensitive tumor cells. Preliminary findings
of infiltrative cells compatible with lymphocytes (Figure 10), seen in IR and HR cases, would agree
with this interpretation. Nevertheless, further histopathological validation will be needed to fully
confirm the identity of these cells and their possible contribution to the recorded metabolic pattern.
The rich information contained in these oscillatory metabolomics pattern changes is discrepant with
the lack of tumor volume changes during the growth arrest phase. New “repopulation” of the tumor
mass with actively proliferating GL261 cells with new clonal characteristics may cause the oscillating
peaks of non-responding tumor (red pixels). The initially activated CD8+ T cells would not be effective
against those new sub-clones of GL261 cells and another cycle of DC priming and new CTL clones
activation would be required.
The participation of the immune system in the response to therapy has been widely described by
different authors [52,53] and GBMs are known to exhibit varying degrees of infiltration with mononuclear
cells, consisting primarily of T lymphocytes, reinforcing the idea of a cell-mediated immune response [54]
although these tumors are also known to secrete a number of immunosuppressive factors. This
intratumoral infiltration with CD4+ and CD8+ T cells was also seen in preclinical glioblastoma (GL26
glioma-bearing C57BL/6 mice) after immunomodulatory treatment [55]. The described GBM infiltration
with T lymphocytes, on the other hand, could be a likely explanation for the appearance of green,
responding pixels even in nosological images of mice which did not receive treatment.
Other evidences also support the hypothesis of the immune system participation in response
to therapy. For example, the use of a metronomic scheme of therapy administration, optimized
in order to activate host immune responses, has been used with excellent results in ectopic GL261
preclinical models [48] even producing the cure of animals, as well as inducing long-term immune
memory against the tumor. Authors in [48] used a six-day interleave period for therapy administration
(cyclophosphamide), demostrating that this interval was optimal in their case for improving the
immune system participation. Metronomic administration, usually referring to administrations of
low and equally spaced doses of chemotherapeutics without long rest periods in between [47,48] has
been used to improve immune responses to potentiate tumor regression and avoid regrowth [48].
Our group has also used this scheme in work reported in [46], obtaining a survival time slightly
higher (38.7 ± 2.7 days, n = 6) than the traditional scheme with three cycles [18] used in the present
work (5-2-2 days with a three-day interleave between them (33.9 ± 11.7 days, n = 38)). Still, work
reported in [46] highlighted the relevance of the metronomic strategy in comparison with traditional
administration schemes in which results suggested an impairment of the immune system related
response due to continuous therapy administration, probably interfering with T cell amplification.
However, it is important to remark that the 5-2-2 cycle therapy does not follow a metronomic
schedule, although data in Figure 2 clearly show a close to six-day oscillation of “responding pixels”
percentage. However, it is true that the 5-2-2 protocol does not follow a metronomic scheme, data
gathered in [18] showed that a single cycle of TMZ during five days did not produce any improvement
in animal survival (20.6 ± 6.8 days for 1 TMZ cycle vs. 20.5 ± 4.1 days for control animals). It was
only when the two additional cycles were introduced with a three-day interleave between them that
the survival rate increased significantly to 33.8 ± 8.7 days. The interleave between the middle time
point of each cycle is, in the 5-2-2 protocol, six days between the first and second cycle, and five days
between the second and third cycle, which could have contributed to configure a “metronomic-like”
therapeutic scheme, favoring the host immune system participation in response to therapy also in
our present study. Nevertheless, it is also possible that the duration of the first TMZ cycle (five days)
partially prevented the full immune cycle recruiting, with a balance between favorable and unfavorable
conditions. The sub-optimal length of TMZ administration could trigger cell damage, both in tumor
cells but also in proliferating primed CD8+ lymphocytes in the lymph nodes, which should later
infiltrate the tumor. Accordingly, the second “response” peak (seen after the second therapy cycle in
Figure 2) would be a mixture of new immune system attraction through immunogenic signaling caused
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by the previous TMZ treatment, and a wave of the remaining CD8+ lymphocytes not compromised
by TMZ administration. Further work will be needed in this sense: if the 6–7-day cycle for immune
system activation is proven correct in our GBM preclinical system, an adjustment of cycles should be
done and the interleave between the first and second cycles should be 6–7 days for future work, as well
as a shortening of the first cycle to a single administration to avoid interfering with T-cell amplification.
In addition, in order to fully characterize the immune system cells differentially present in responding
and non-responding zones (red and green patterns in nosological imaging), additional immunostaining
methods may be applied, such as CD8a and foxP3 as described in [56]. This would be of help to better
understand potential contributors to the metabolomics pattern of responding and non-responding tumor
zones. Last, but not least, the nosological images here described could be of relevance to design personalized
therapeutic schemes, being able to detect when a tumor starts failing to respond to a first line therapy,
providing a time frame for considering a second line or a combination therapy approach.
4. Materials and Methods
4.1. GL261 Cells
GL261 mouse glioma cells were obtained from the Tumour Bank Repository at the National
Cancer Institute (Frederick, MD, USA) and were grown as previously described [27].
4.2. Preclinical Glioblastoma Model for in vivo Studies
The use of animals in this study has been reported according to the ARRIVE guidelines [57].
Animals were obtained from Charles River Laboratories (L’Abresle, France) and housed in the
animal facility of the Universitat Autònoma de Barcelona. All mice described in this work are identified
with a unique alphanumeric identifier of the type CXXXX. Tumors were induced in a total of 39
C57BL/6 female wild-type (wt) mice (weighing 21.1 ± 1.3 g) by intracranial stereotactic injection of
105 GL261 cells as previously described by us [26], although not all of them were selected for therapy
administration (final number of included animals n = 26). In addition, not all animals receiving therapy
met criteria for inclusion in classes described in Section 4.5, resulting in a final number of studied
animals being lower than the initial number of generated animals.
Still, two different groups of animals were produced:
Group A: Tumors were generated in different series of animals separately in time for proper
schedule allocation in the NMR facility. In the first part of the study, 5–7 animals were injected in each
cell-injection series. Mice were weighed every day and tumor volumes were followed twice or three
times a week using T2-weighted MRI acquisition (welfare parameters were followed up as explained
in Table S2). From the animals injected in each series, the three mice with the most homogeneous
weights and tumor sizes were chosen for the multi-slice MRSI experiment before starting therapy.
Group B: In the second part of the study, tumors were induced in 19 mice. Four of them were
discarded because no tumor was detected after 10 days p.i. Regarding the remaining 15 mice, they were
weighed every day and tumor volumes were followed twice or three times a week using T2-weighted
MRI acquisition in all generated tumor-bearing animals. However, only mice showing tumor volume
decrease after therapy (see next section for therapy details), in comparison with previous measurement,
were selected for multi-slice MRSI experiments.
In addition, four control (non treated) tumor-bearing mice were also explored by multi-slice MRSI.
4.3. Animal Treatment with Temozolomide
TMZ (Sigma-Aldrich, Madrid, Spain) was dissolved in 10% DMSO in saline solution (0.9% NaCl)
for in vivo experiments and it was administered using an oral gavage at a dose of 60 mg/kg as in [18].
In the first part of the study (group A), therapy administration started at Day 11 p.i. (tumor volume
average 7.5± 5.0 mm3) with 3 cycles of therapy administration as previously described by our group [18].
Schema of TMZ administration is shown in Figure S9. In the second part of the study (group B), the therapy
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starting day was not always the same, being adapted to start when the tumor volume was between 3 and
5 mm3 ± 10%.
All studies were approved by the local ethics committee (Comissió d’Ètica en Experimentació Animal
i Humana (CEEAH), http://www.recerca.uab.es/ceeah accessed on 16 November 2016), according to
the regional and state legislation (protocol DMAH-8236/CEEAH-2785).
4.4. In vivo MRI and MRSI Studies
4.4.1. Data Acquisition
In vivo MRI/MRSI studies were performed at the joint nuclear magnetic resonance facility
of the Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red—Bioingeniería,
Biomateriales y Nanomedicina (CIBER-BBN) (Cerdanyola del Vallès, Spain), Unit 25 of NANBIOSIS. The 7T
Bruker BioSpec 70/30 USR spectrometer (Bruker BioSpin GmbH, Ettlingen, Germany) equipped with
a mini-imaging gradient set (400 mT/m) was used. A 72 mm inner diameter linear volume coil was
used as transmitter, and a mouse brain surface coil as a receiver for brain MRI studies.
Mice were positioned in a bed, which allowed delivery of anaesthesia (isoflurane, 1.5–2.0% in O2
at 1 L/min), with an integrated heating water circuit for body temperature regulation. Respiratory
frequency was monitored with a pressure probe and kept between 60–80 breaths/min.
• MRI studies
GL261 tumor-bearing mice were screened by acquiring high resolution coronal T2w images using a
Rapid Acquisition with Relaxation Enhancement (RARE) sequence to detect brain tumor presence and to
monitor its evolution stage. The acquisition parameters were as follows: repetition time (TR)/effective
echo time (TEeff ) = 4200/36 ms; echo train length (ETL) = 8; field of view (FOV) = 19.2× 19.2 mm; matrix
size (MTX) = 256 × 256 (75 × 75 µm/pixel); number of slices (NS) = 10; slice thickness (ST) = 0.5 mm;
inter-ST = 0.1 mm; number of averages (NA) = 4; total acquisition time (TAT) = 6 min and 43 s.
MRI data were acquired and processed on a Linux computer using ParaVision 5.1 software (Bruker
BioSpin GmbH, Ettlingen, Germany).
• MRSI studies
Consecutive 14 ms TE MRSI with PRESS localization grids were acquired individually across the
tumor, using as a reference T2w high resolution images, as shown in Figure 12. First upper (dorsal)
grid (Grid 1) had a matrix size of 10 × 10. Then, Grid 2 was acquired 1 mm below Grid 1 with a matrix
size of 12 × 12. Grid 3 was acquired 1 mm below Grid 2, with a matrix size of 12 × 12. Finally, if tumor
volume was not completely covered with 3 grids, a last Grid 4 was acquired 1mm below Grid 3 with
a matrix size of 10 × 10. In order to ensure quality of the acquired data, shimming was performed
individually for each MRSI grid. MRSI grids were spatially located such that the volume of interest
(VOI) included most of the tumoral mass as well as normal/peritumoral brain parenchyma.
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• MRI studies 
GL261 tumor-bearing mice were scree ed by acquiring high resolution coronal T2w images using 
a Rapid Acquisition with Relaxation Enhancement (RARE) sequence to detect brain tumor presence 
and to monitor its evolution stage. The acquisition parameters were as follows: repetition time 
(TR)/effective echo time (TEeff ) = 4200/36 ms; echo train length (ETL) = 8; field of view (FOV) = 19.2 × 19.2 
m; matrix size (MTX) = 256 × 256 (75 × 75 µm/pixel); number of slices (NS) = 10; slice thickness (ST) = 
0.5 mm; inter-ST = 0.1 mm; number of averages (NA) = 4; total acquisition time (TAT) = 6 min and 43 s. 
MRI data were acquired and processed on a Linux computer using ParaVision 5.1 software 
(Bruker BioSpin GmbH, Ettlingen, Germany). 
• MRSI studies 
Consecutive 14 ms TE MRSI with PRESS localization grids were acquired individually across the 
tumor, using as a reference T2w high resolution images, as shown in Figure 12. First upper (dorsal) grid 
(Grid 1) had a matrix size of 10 × 10. Then, Grid 2 was acquired 1 mm below Grid 1 with a matrix size 
of 12 × 12. Grid 3 was acquired 1 mm below Grid 2, with a matrix size of 12 × 12. Finally, if tumor volume 
was not completely covered with 3 grids, a last Grid 4 was acquired 1mm below Grid 3 with a matrix 
size f 10 × 10. In order to ensure quality of the acquired d ta, shimming was performed individually 
for each MRSI grid. MRSI grids were spatially located such that the volume of interest (VOI) included 
most of the tumoral mass as well as normal/peritumoral brain parenchyma. 
 
Figure 12. Coronal T2w MRI of mouse C971 brain, with the position of the four MRSI slices. 
Figure 12. Coronal T2w MRI of mouse C971 brain, with the position of the four MRSI slices.
Metabolites 2017, 7, 20 22 of 29
Acquisition parameters for all grids were: FOV, 17.6 mm × 17.6 mm; VOI in Grids 1 and 4 was
5.5 mm × 5.5 mm × 1.0 mm. VOI in Grids 2 and 3 was 6.6 mm × 6.6 mm × 1.0 mm. ST, 1 mm; TR,
2500 ms; Sweep Width (SW), 4006.41 Hz; NA, 512; TAT, 21 min 30 s. Water suppression was performed
with Variable Power and Optimized Relaxation Delay (VAPOR), using a 300 Hz bandwidth. Linear
and second order shims were automatically adjusted with Fast Automatic Shimming Technique by
Mapping Along Projections (FASTMAP) in a 5.8 mm × 5.8 mm × 5.8 mm volume which contained the
VOI region. Six saturation slices (ST, 10 mm; sech-shaped pulses: 1.0 ms/20250 Hz) were positioned
around the VOI to minimize outer volume contamination in the signals obtained. Total acquisition
time for a typical MRI/MRSI 4 grids full protocol was about 3.5 h.
In the first part of the study, MRSI experiments were acquired every 2–3 days, from the day
before starting therapy until animal euthanization. However, in the second part of the study, MRSI
experiments were not acquired from the beginning of therapy administration. Tumor volume
was followed up by MRI and when tumor size was reduced, compared to the volume observed
in the previous MRI measurement, MRSI studies started to be carried out every 2–3 days until
animal euthanization.
4.4.2. MRI and MRSI Processing and Post Processing
• Volume calculation
Manual segmentation of abnormal brain mass in T2w images was performed by LF, and tumor
volumes were calculated from T2w high resolution horizontal images using the equation:
TV (mm3) = [(AS1 × ST) + [(AS2 + (. . .) + AS10) × (ST + IT)]] × 0.0752 (1)
where TV is the tumor volume, AS is the number of pixels contained in the region of interest delimited
by the tumor boundaries in each slice of the MRI sequence, ST is the slice thickness (0.5 mm), IT the
inter-slice thickness (0.1 mm) and 0.0752 mm2 the individual pixel surface area. The tumor area was
calculated from pixels in each slice, using an automated system for generating regions of interest
(ROIs) available in the ParaVision 5.1 software (Bruker BioSpin, Ettlingen, Germany). The inter-slice
volume was not registered and it was estimated adding the inter-slice thickness to the corresponding
slice thickness in Equation (1).
• Brain MRSI post-processing and pattern recognition (PR) strategies
MRSI data were post-processed essentially as described in [27]. Briefly, data were initially
pre-processed at the MR workstation with ParaVision 5.1 (Bruker BioSpin), and then post-processed
with 3D Interactive Chemical Shift Imaging (3DiCSI) software package version 1.9.17 (Courtesy of
Truman Brown, Ph.D., Columbia University, New York, NY, USA) for line broadening adjustment
(Lorentzian filter, 4 Hz), zero-order phase correction and exporting the data in ASCII format. Dynamic
MRSI processing Module (DMPM), running over MatLab 2013a (The MathWorks Inc., Natick,
MA, USA) was used to align all spectra within each MRSI matrix (using the choline containing
compounds peak as reference, 3.21 ppm). The 0–4.5 ppm region of each spectrum in the MRSI matrix
was individually normalized to UL2 and the normalized matrix was exported in ASCII format for
performing the PR analysis. No baseline correction was performed in these spectra.
After that, the NMF semi-supervised methodology [58,59] was applied for the extraction of
meaningful source signals from the MRSI investigated tumors. In general, non-negative matrix
factorization (NMF) methods belong to a group of multivariate data analysis techniques designed to
estimate meaningful latent components, also known as sources, from non-negative data. Standard
NMF methods decompose a given data matrix “X” into two non-negative matrices: the sources (“S”)
and the mixing matrix (“A”). The differences between these NMF methods are given by the different
cost functions used for measuring the divergence between X and S*A. In addition, convex NMF, used
in this work, is also able to handle negative data [59,60].
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From the biochemical viewpoint, the source extraction technique to classify MRS data assumes that
in each voxel there is a mixture of heterogeneous tissues and its metabolites from which the contribution
of each source can be obtained. A previously described semi-supervised approach [13], based on
cNMF for initial source extraction, was used for classifying pixels into normal brain parenchyma,
actively proliferating tumor and tumor responding to treatment; and for calculating nosologic maps
representing the spatial response to treatment, as in [13]. Green color is used when the GBM
responding to treatment source contributes the most, blue for normal brain parenchyma, red for
actively proliferating GBM and black for undetermined tissue.
4.5. Tumor Responding Index (TRI) Calculations
In order to measure the level of response to treatment using the obtained nosological images, an
arbitrary parameter named TRI was estimated (Equation (2)).
TRI =
Tumour responding pixels
Total tumour pixels
× 100 (2)
TRI is stated as the percentage of green responding tumor pixels of all grids over the total tumor pixels
of all recorded grids. Then, tentative ranges of TRI categories were established to classify the different
response to treatment levels observed in the studied animals, taking into account both TRI percentage and
volumetric data from MRI measurements meeting “stable disease” criteria according to RECIST [5].
High response cases (HR): TRI > 65%, and also tumor size should be reduced with respect to
tumor volume observed in the previous MRI measurement. Green pixels must be observed in at least
two consecutive MRSI grids
Intermediate response cases (IR): TRI range 35–65%, also tumor size should be unchanged,
reduced or not increase more than 20% with respect to tumor volume observed in the previous
measurement (response or stable disease stage by RECIST criteria) and green pixels must be observed
in at least two consecutive MRSI grids
Low response cases (LR): TRI < 35% and also tumor size must be more than 20% larger in
comparison with the previous measurement.
Animal Euthanasia and Sample Storage
Animals were followed up by MRI-MRSI and when one animal met the requirements to be
included in one of the TRI categories, this animal was euthanized by cervical dislocation and its brain
was resected and saved in paraformaldehyde 4% for histopathological analysis.
4.6. Histopathology Studies
Fixed brain was embedded in paraffin and serial horizontal sections were performed to correlate
the histological preparations with the reference nosological images from the MRSI acquisition.
The upper half of the brain (similar to the positions of MRSI Grid 1 and MRSI Grid 2) was cut
in 20 sections of 5 µm, and the lower half of the brain (similar to the positions of MRSI Grids 3 and 4)
was also cut in 20 sections of 5 µm.
These sections were analyzed by Hematoxylin-Eosin (HE) staining in order to identify the different
cells from normal brain and tumor tissue. Then, one section corresponding to each MRSI grid position
was selected for Ki67 (BD Biosciences, Madrid, Spain) immunohistochemical staining for detecting
cell proliferation. After immunostaining, the preparations were digitized for quantification using a
Nanozoomer 2.0HT (Hamamatsu Photonics France, Massy, France). Then, Ki67 positive cells were counted
in each section in areas that corresponded to green or red tumor areas observed in the nosological images.
From each area (either green or red), 5 fields of 0.0635 mm2 were selected to count Ki67 positive cells at
40×magnification, using NDPview 1.2.53 software (Hamamatsu Photonics France SARL, Massy, France).
In all tumors, we have placed the five fields in more highly cellular areas (either green or red), avoiding
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poor or acellular areas. Exceptionally, in some samples, fewer fields were counted if the corresponding
green or red area of the nosological image was not large enough to count 5 fields (mean numbers of fields
counted considering all samples: 6.3± 2.1 of fields counted per grid)
This counting was carried out by 2 different people: one who established the areas (green or red)
to be counted, placing fields in areas where cells were observed, and a second observer, who did not
know if the animal was treated one or not, or if the field to be analyzed corresponded to a green or red
area. The 2 different observers evaluated in every picture, at the same magnification, the area occupied
by cells and acellular spaces, giving a percentage for each parameter.
For Ki67, different approaches of counting were attempted, namely:
Ki67% for each field was calculated as described in Equation (3):
Number o f tumoral Ki67 positive cells
Number o f total tumoral cells
× 100 (3)
Global Ki67% for each case was calculated as the mean Ki67% of all analyzed fields.
Ki67/mm2, was calculated for each field as described in Equation (4):
Number o f tumoral Ki67 positive cells
Field area (mm2)
(4)
where field area was 0.0635 mm2 in the studied fields.
Finally, the volume of Ki67 positive cells was calculated through measures of the mean diameter
of cells in chosen fields, which was used with the sphere volume formula, assuming cells with a
spherical form.
4.7. Statistical Analysis
Data was evaluated for compliance with the normal distribution using the Shapiro–Wilk and
Kolmogorov–Smirnov tests. The presence of outliers in samples was tested with Grubb’s and Dixon’s
tests. Variance homogeneity was evaluated with the Levene’s test. A two-tailed Student’s t-test for
independent measurements was used for comparisons, for samples of equal or different variances
(depending on the Levene’s test result) in case of samples following a normal distribution; and
Mann–Whitney’s U test was applied to samples following non-normal distributions. The global
evolution of body weight measurements was evaluated with the UNIANOVA test. The significance
level for all tests was p < 0.05.
5. Conclusions
A multi-slice MRSI, non-invasive recording approach is feasible in our preclinical model and
may be beneficial to properly evaluate the overall therapy response in preclinical GBM. This approach
may be used to generate volumetric nosological maps to follow-up treatment and plan on further
therapy. Histopathological studies with global Ki67 confirmed results from previous work from
our group in which an inverse correlation is seen between the responding pattern level and Ki67
proliferation rate. Still, we could break down responding cases in different response levels calculated
from nosological imaging, which, accordingly, were related to global Ki67 for each of those cases.
However, a word of caution should be raised when interpreting Ki67 data from cases with widely
different cell morphology and volumes, as this could cause an apparent mismatch between Ki67 and
metabolomics data producing nosological images.
The tumor responding index calculated from nosological images showed an oscillating pattern with
peak maxima every 6–7 days, which would be in agreement with host immune system recruitment for
therapy response in our experimental GBM model. This is in agreement with histopathological findings of
lymphocyte-like cells infiltrating IR and HR cases but not observed in LR and control cases. Further work
on infiltrating immune cells characterization will be needed to confirm or discard this hypothesis.
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group, Figure S2: Mean ± SD evolution of body weight of mice studied by multi-slice MRSI, Figure S3: Graphical
representation of the tumor volume evolution, and the percentage of responding “green” pixels obtained after
NMF analysis of MRSI data acquired in the multi-slice set as in [13], Figure S4: Comparison of responding/non
responding spectral patterns with expansions in some differential zones with tentative metabolite assignment as in
Figure 5 and Table 1, Figure S5: Ki67 immunostainings in histological areas corresponding to red or green regions
in nosological images, from different grids of chosen cases, Figure S6: Graph bars representing global Ki67%
values, Figure S7: Boxplot of global number of Ki67 positive cells/mm2 of different groups of cases classified
by TRI response, Figure S8: (A). Boxplot of volume of Ki67 positive cells in each TRI group; (B). Representation
of percentage of acellular spaces observed in different TRI groups, Figure S9: TMZ administration schema with
3 therapy cycles with a 3-day interleave, as described previously by us [18], Table S1: Data summary of tumor
volume the day before starting therapy administration and the day in which euthanasia was carried out, Table S2:
Welfare parameters followed up in the study.
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Abbreviations
Ala Alanine
Cho Choline
Cre Creatine
CTLs Cytotoxic T-lymphocytes
DMPM Dynamic MRSI processing Module
DWI Diffusion Weighted Imaging
ETL Echo train length
FOV Field of view
GABRMN Grup d’Aplicacions Biomèdiques de la RMN
GBM Glioblastoma
GIC Glioma-initiating cells
Glx Glutamine + glutamate
HE Hematoxylin-eosin
HR High response
IQR Interquartile range
Ins + Gly Myo-inositol + glycine
IR Intermediate response
Lac Lactate
LR Low response
ML Mobile lipids
MM Macromolecules
MTX Matrix size
NA Number of averages
NAA N-acetyl-aspartate
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NAc N-acetyl group containing compounds
NMF Non-negative matrix factorization
NS Number of slices
PBS Phosphate-buffered saline
p.i. Post-inoculation
ppm parts per million
PR Pattern recognition
PUFA Polyunsaturated fatty acids
RANO Response assessment in neuro-oncology
RARE Rapid acquisition with relaxation enhancement
ST Slice thickness
TAT Total acquisition time
TEeff Effective echo time
TMZ Temozolomide
TR Repetition time
TRI Tumor responding index
VOI Volume of interest
3DiCSI 3D interactive chemical shift imaging
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